<div id="readability-page-1"><p>Summit Therapeutics PLC (<span>SMMT</span>) has disclosed a new risk, in the Debt &amp; Financing category.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Summit Therapeutics PLC is exposed to material going-concern risk, as its existing cash, cash equivalents, and short-term investments are insufficient to fund planned operations for the twelve months following issuance of its March 31, 2026 unaudited financial statements. The company’s reliance on uncertain external financing heightens the prospect of operational cutbacks, program delays, or an eventual cessation of activities if capital cannot be raised on acceptable terms.</p> <p>The average SMMT <span>stock price target</span> is $31.25, implying 93.92% upside potential.</p> <p>To learn more about Summit Therapeutics PLC’s risk factors, <span>click here</span>.</p></div>

SMMT

SBIO

IBBQ

LABU

<p>Summit Therapeutics PLC (SMMT) has flagged a significant going-concern risk due to insufficient cash and short-term investments to fund operations for the next twelve months. The company's reliance on uncertain external financing may lead to operational cutbacks or cessation of activities if capital cannot be raised. Despite this, the average stock price target is $31.25, indicating a potential upside of 93.92%.</p>

Tip Ranks

Summit Therapeutics

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing